SEC Filing Summary: AntriaBio, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AntriaBio, Inc. (not Rezolute, Inc.) with a report date of September 30, 2016, covering events occurring on September 30, 2016, and October 6, 2016. The filing details the completion of additional closes for a private placement transaction (PIPE Financing) and the entry into a material definitive agreement regarding a placement agent.
Key Financial Metrics
- Gross Cash Proceeds: $4.8 million (excluding placement agent compensation, transaction costs, fees, and expenses).
- Securities Issued: Aggregate of 4,405,909 Units (Class A and Class B).
- Unit Pricing: $1.10 per Unit.
- Warrant Exercise Price: $1.65 per share.
- Warrant Term: 60 months (5 years) from the Close date.
- Placement Agent Fees: 13% cash fee on gross proceeds; 3% cash fee on warrant exercises; 10% warrant fee based on gross proceeds.
Material Changes and Transaction Details
The Company completed a PIPE Financing under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. The transaction involved the issuance of Class A Units (one share of common stock plus one-half warrant) and Class B Units (one share of common stock plus one full warrant) to investors. Class B Units were reserved for investors who had previously invested in AntriaBio and invested a minimum of $50,000 in this specific financing. Additionally, the Company granted registration rights to investors and the placement agent, agreeing to file a registration statement within 90 days of the Close.
Outlook, Risks, and Contingencies
The filing notes that the securities offered have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption. The Company is obligated to maintain the effectiveness of the registration statement until legal counsel confirms the shares are available for resale under Rule 144. The filing explicitly states it is not an offer to sell securities nor a solicitation to purchase them.
Investor Verification Checklist
- Verify the total dilution impact of the 4,405,909 Units issued plus the associated warrants.
- Confirm the net cash proceeds after deducting the 13% placement agent fee and other transaction costs.
- Review the status of the registration statement filing required within 90 days of the Close.
- Assess the Company's current cash runway given the $4.8 million gross raise.
- Check for any subsequent filings regarding the effectiveness of the registration statement.